InfuSystem (NYSE:INFU) Upgraded to Strong-Buy at Sidoti

InfuSystem (NYSE:INFU) was upgraded by Sidoti to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Separately, StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 14th.

InfuSystem Price Performance

Shares of InfuSystem stock opened at $5.72 on Tuesday. The stock has a market capitalization of $120.17 million, a price-to-earnings ratio of 95.35 and a beta of 1.75. InfuSystem has a 1-year low of $5.29 and a 1-year high of $9.97. The firm’s 50-day moving average price is $7.51 and its two-hundred day moving average price is $7.55. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Institutional Investors Weigh In On InfuSystem

Hedge funds have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. increased its position in shares of InfuSystem by 28.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock worth $223,000 after acquiring an additional 7,295 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of InfuSystem by 66.4% in the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares during the last quarter. Barclays PLC increased its position in shares of InfuSystem by 300.5% during the 3rd quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after purchasing an additional 21,457 shares during the last quarter. Geode Capital Management LLC lifted its position in InfuSystem by 1.8% in the third quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after purchasing an additional 7,550 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in InfuSystem by 74.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after purchasing an additional 6,623 shares during the period. 71.13% of the stock is currently owned by institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.